KALA BIO, Inc. (KALA): restructuring charge — KALA halts pipeline, cuts 51% of staff, grants retention bonuses to top executives

KALA BIO, Inc.

Ceased development of KPI-012 and stem cell platform; workforce reduced by ~19 employees (~51%).
Expects ~$0.4M in restructuring costs (severance/benefits), substantially in Q4 2025.
Entered retention agreements: CEO Todd Bazemore ($183,750), CFO Mary Reumuth ($136,250), CMO Kim Brazzell ($145,000).
Company preserving cash while exploring strategic alternatives.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

KALA BIO, Inc. announced a restructuring with charges of approximately $0.4 million affecting KPI-012 and its mesenchymal stem cell secretome platform (approximately 19 employees, or approximately 51%).

Type: restructuring
Charge: approximately $0.4 million
Affected area: KPI-012 and its mesenchymal stem cell secretome platform
Headcount: approximately 19 employees, or approximately 51%

Exact text from the filing

generally accepted accounting principles as a result of the Reduction. Subsequent to the Original Report, the Company determined that it expects to incur costs of approximately $0.4 million related to the Reduction, primarily consisting of severance payments and employee benefit costs. The costs related to the Reduction are expected to be substantially incurred in

View on SEC.gov

Browse all restructurings & charges →

KALA BIO, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-096071

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.